Sinocare(300298) 民生证券·2025-04-21 09:21Investment Rating - The report maintains a "Recommended" rating for the company [4][6]. Core Viewpoints - The company achieved a revenue of 4.443 billion yuan in 2024, representing a year-on-year increase of 9.47%, with overseas revenue accounting for 41.98% [1]. - The company is positioned as a leader in the domestic blood glucose monitoring retail market, holding nearly 50% market share and serving over 22 million users [3]. - The company is actively expanding its global presence, with products registered and sold in over 60 countries, including the U.S. and various European nations [2][3]. Financial Performance Summary - In 2024, the company reported a net profit of 326 million yuan, up 14.73% year-on-year [1]. - The projected revenues for 2025, 2026, and 2027 are 4.942 billion yuan, 5.539 billion yuan, and 6.270 billion yuan, respectively, with growth rates of 11.2%, 12.1%, and 13.2% [4][5]. - The net profit forecasts for the same years are 480 million yuan, 560 million yuan, and 675 million yuan, with growth rates of 47.2%, 16.7%, and 20.5% [5][7]. Cost and Profitability Metrics - The gross profit margin for Q4 2024 was 54.01%, showing a slight decrease compared to the previous year [1]. - The company has optimized its expense ratios, with R&D expense ratio at 7.65%, sales expense ratio at 27.72%, and management expense ratio at 6.24% [1]. Market Position and Strategy - The company has developed a comprehensive chronic disease management system, collaborating with over 3,800 hospitals and providing services to more than 10,000 community hospitals [3]. - The company is leveraging e-commerce to expand its reach, covering 187 countries and regions, and establishing local logistics in 18 countries [3].